Eledon Pharma Files Amendment on Certifying Accountant
Ticker: ELDN · Form: 8-K/A · Filed: Apr 14, 2025 · CIK: 1404281
| Field | Detail |
|---|---|
| Company | Eledon Pharmaceuticals, Inc. (ELDN) |
| Form Type | 8-K/A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, auditor-change, financials
TL;DR
Eledon Pharma amended its filing about a new auditor - check the financials.
AI Summary
Eledon Pharmaceuticals, Inc. filed an amendment (8-K/A) on April 14, 2025, to its previous filing regarding changes in its certifying accountant. The amendment pertains to events that occurred on April 1, 2025, and involves the company's financial statements and exhibits.
Why It Matters
This filing indicates a change in Eledon Pharmaceuticals' auditor, which could impact financial reporting and investor confidence.
Risk Assessment
Risk Level: low — This is an administrative amendment regarding a change in auditor, not a material event impacting the company's operations or financial health.
Key Players & Entities
- Eledon Pharmaceuticals, Inc. (company) — Registrant
- April 14, 2025 (date) — Filing date of amendment
- April 01, 2025 (date) — Earliest event date reported
- Novus Therapeutics, Inc. (company) — Former company name
- Tokai Pharmaceuticals Inc (company) — Former company name
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, specifically addressing changes in the Registrant's certifying accountant and related financial statements and exhibits.
When was this amendment filed with the SEC?
The amendment was filed on April 14, 2025.
What is the earliest event date reported in this filing?
The earliest event date reported is April 01, 2025.
What were Eledon Pharmaceuticals' former company names?
Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. (name change on 20170511) and Tokai Pharmaceuticals Inc (name change on 20070622).
What is Eledon Pharmaceuticals' principal executive office address?
The principal executive offices are located at 19800 MacArthur Blvd. Suite 250, Irvine, California, 92612.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on April 14, 2025 regarding Eledon Pharmaceuticals, Inc. (ELDN).